Stem cell collection and gene transfer in fanconi anemia

Patrick F. Kelly, Susan Radtke, Cristof von Kalle, Brenden Balcik, Kimberley Bohn, Robin Mueller, Todd Schuesler, Moira Haren, Lilith Reeves, Jose A. Cancelas, Thomas Leemhuis, Richard Harris, Arleen D. Auerbach, Franklin O. Smith, Stella M. Davies, David A. Williams

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Fanconi anemia (FA) is a rare genetic syndrome characterized by progressive bone marrow failure (BMF), congenital anomalies, and a predisposition to malignancy. Successful gene transfer into hematopoietic stem cells (HSCs) could reverse BMF in this disease. We developed clinical trials to determine whether a sufficient number of CD34+ stem cells could be collected for gene modification and to evaluate the safety and efficacy of HSC-corrective gene transfer in FA genotype A (FANCA) patients. Here, we report that FA patients have significant depletion of their BM CD34+ cell compartment even before severe pancytopenia is present. However, oncoretroviral-mediated ex vivo gene transfer was efficient in clinical scale in FA-A cells, leading to reversal of the cellular phenotype in a significant percentage of CD34+ cells. Re-infusion of gene-corrected products in two patients was safe and well tolerated and accompanied by transient improvements in hemoglobin and platelet counts. Gene correction was transient, likely owing to the low dose of gene-corrected cells infused. Our early experience shows that stem cell collection is well tolerated in FA patients and suggests that collection be considered as early as possible in patients who are potential candidates for future gene transfer trials.

Original languageEnglish (US)
Pages (from-to)211-219
Number of pages9
JournalMolecular Therapy
Volume15
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Fanconi Anemia
Stem Cells
Genes
Hematopoietic Stem Cells
Bone Marrow
Pancytopenia
Platelet Count
Hemoglobins
Genotype
Clinical Trials
Phenotype
Safety

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Kelly, P. F., Radtke, S., von Kalle, C., Balcik, B., Bohn, K., Mueller, R., ... Williams, D. A. (2007). Stem cell collection and gene transfer in fanconi anemia. Molecular Therapy, 15(1), 211-219. https://doi.org/10.1038/sj.mt.6300033

Stem cell collection and gene transfer in fanconi anemia. / Kelly, Patrick F.; Radtke, Susan; von Kalle, Cristof; Balcik, Brenden; Bohn, Kimberley; Mueller, Robin; Schuesler, Todd; Haren, Moira; Reeves, Lilith; Cancelas, Jose A.; Leemhuis, Thomas; Harris, Richard; Auerbach, Arleen D.; Smith, Franklin O.; Davies, Stella M.; Williams, David A.

In: Molecular Therapy, Vol. 15, No. 1, 01.2007, p. 211-219.

Research output: Contribution to journalArticle

Kelly, PF, Radtke, S, von Kalle, C, Balcik, B, Bohn, K, Mueller, R, Schuesler, T, Haren, M, Reeves, L, Cancelas, JA, Leemhuis, T, Harris, R, Auerbach, AD, Smith, FO, Davies, SM & Williams, DA 2007, 'Stem cell collection and gene transfer in fanconi anemia', Molecular Therapy, vol. 15, no. 1, pp. 211-219. https://doi.org/10.1038/sj.mt.6300033
Kelly PF, Radtke S, von Kalle C, Balcik B, Bohn K, Mueller R et al. Stem cell collection and gene transfer in fanconi anemia. Molecular Therapy. 2007 Jan;15(1):211-219. https://doi.org/10.1038/sj.mt.6300033
Kelly, Patrick F. ; Radtke, Susan ; von Kalle, Cristof ; Balcik, Brenden ; Bohn, Kimberley ; Mueller, Robin ; Schuesler, Todd ; Haren, Moira ; Reeves, Lilith ; Cancelas, Jose A. ; Leemhuis, Thomas ; Harris, Richard ; Auerbach, Arleen D. ; Smith, Franklin O. ; Davies, Stella M. ; Williams, David A. / Stem cell collection and gene transfer in fanconi anemia. In: Molecular Therapy. 2007 ; Vol. 15, No. 1. pp. 211-219.
@article{48ba1d583a3646688c8c9ec10bc5da9a,
title = "Stem cell collection and gene transfer in fanconi anemia",
abstract = "Fanconi anemia (FA) is a rare genetic syndrome characterized by progressive bone marrow failure (BMF), congenital anomalies, and a predisposition to malignancy. Successful gene transfer into hematopoietic stem cells (HSCs) could reverse BMF in this disease. We developed clinical trials to determine whether a sufficient number of CD34+ stem cells could be collected for gene modification and to evaluate the safety and efficacy of HSC-corrective gene transfer in FA genotype A (FANCA) patients. Here, we report that FA patients have significant depletion of their BM CD34+ cell compartment even before severe pancytopenia is present. However, oncoretroviral-mediated ex vivo gene transfer was efficient in clinical scale in FA-A cells, leading to reversal of the cellular phenotype in a significant percentage of CD34+ cells. Re-infusion of gene-corrected products in two patients was safe and well tolerated and accompanied by transient improvements in hemoglobin and platelet counts. Gene correction was transient, likely owing to the low dose of gene-corrected cells infused. Our early experience shows that stem cell collection is well tolerated in FA patients and suggests that collection be considered as early as possible in patients who are potential candidates for future gene transfer trials.",
author = "Kelly, {Patrick F.} and Susan Radtke and {von Kalle}, Cristof and Brenden Balcik and Kimberley Bohn and Robin Mueller and Todd Schuesler and Moira Haren and Lilith Reeves and Cancelas, {Jose A.} and Thomas Leemhuis and Richard Harris and Auerbach, {Arleen D.} and Smith, {Franklin O.} and Davies, {Stella M.} and Williams, {David A.}",
year = "2007",
month = "1",
doi = "10.1038/sj.mt.6300033",
language = "English (US)",
volume = "15",
pages = "211--219",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Stem cell collection and gene transfer in fanconi anemia

AU - Kelly, Patrick F.

AU - Radtke, Susan

AU - von Kalle, Cristof

AU - Balcik, Brenden

AU - Bohn, Kimberley

AU - Mueller, Robin

AU - Schuesler, Todd

AU - Haren, Moira

AU - Reeves, Lilith

AU - Cancelas, Jose A.

AU - Leemhuis, Thomas

AU - Harris, Richard

AU - Auerbach, Arleen D.

AU - Smith, Franklin O.

AU - Davies, Stella M.

AU - Williams, David A.

PY - 2007/1

Y1 - 2007/1

N2 - Fanconi anemia (FA) is a rare genetic syndrome characterized by progressive bone marrow failure (BMF), congenital anomalies, and a predisposition to malignancy. Successful gene transfer into hematopoietic stem cells (HSCs) could reverse BMF in this disease. We developed clinical trials to determine whether a sufficient number of CD34+ stem cells could be collected for gene modification and to evaluate the safety and efficacy of HSC-corrective gene transfer in FA genotype A (FANCA) patients. Here, we report that FA patients have significant depletion of their BM CD34+ cell compartment even before severe pancytopenia is present. However, oncoretroviral-mediated ex vivo gene transfer was efficient in clinical scale in FA-A cells, leading to reversal of the cellular phenotype in a significant percentage of CD34+ cells. Re-infusion of gene-corrected products in two patients was safe and well tolerated and accompanied by transient improvements in hemoglobin and platelet counts. Gene correction was transient, likely owing to the low dose of gene-corrected cells infused. Our early experience shows that stem cell collection is well tolerated in FA patients and suggests that collection be considered as early as possible in patients who are potential candidates for future gene transfer trials.

AB - Fanconi anemia (FA) is a rare genetic syndrome characterized by progressive bone marrow failure (BMF), congenital anomalies, and a predisposition to malignancy. Successful gene transfer into hematopoietic stem cells (HSCs) could reverse BMF in this disease. We developed clinical trials to determine whether a sufficient number of CD34+ stem cells could be collected for gene modification and to evaluate the safety and efficacy of HSC-corrective gene transfer in FA genotype A (FANCA) patients. Here, we report that FA patients have significant depletion of their BM CD34+ cell compartment even before severe pancytopenia is present. However, oncoretroviral-mediated ex vivo gene transfer was efficient in clinical scale in FA-A cells, leading to reversal of the cellular phenotype in a significant percentage of CD34+ cells. Re-infusion of gene-corrected products in two patients was safe and well tolerated and accompanied by transient improvements in hemoglobin and platelet counts. Gene correction was transient, likely owing to the low dose of gene-corrected cells infused. Our early experience shows that stem cell collection is well tolerated in FA patients and suggests that collection be considered as early as possible in patients who are potential candidates for future gene transfer trials.

UR - http://www.scopus.com/inward/record.url?scp=33845993292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845993292&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300033

DO - 10.1038/sj.mt.6300033

M3 - Article

C2 - 17164793

AN - SCOPUS:33845993292

VL - 15

SP - 211

EP - 219

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -